Background-Incidence of cerebral microinfarcts is higher after transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR). It is unknown whether these lesions persist and what direct impact they have on health-related quality of life. The objective was to identify predictors of cerebral microinfarction and measure their effect on health-related quality of life during 6 months after TAVI when compared with SAVR. Methods and Results-Cerebral MRI was conducted at baseline, post procedure, and 6 months using diffusion-weighted imaging. Health-related quality of life was measured at baseline, 30 days, and 6 months with short form-12 health outcomes and EuroQol 5 dimensions questionnaires. One hundred eleven patients (TAVI, n=71; SAVR, n=40) were studied. The incidence (54 [77%] versus 17 [43%]; P=0.001) and number (3.4±4.9 versus 1.2±1.8; P=0.001) of new microinfarcts were greater after TAVI than after SAVR. The total volume per microinfarct was smaller in TAVI than in SAVR (0.23±0.24 versus 0.76±1.8 mL; P=0.04). The strongest associations for microinfarction were: TAVI (arch atheroma grade: r=0.46; P=0.0001) and SAVR (concomitant coronary artery bypass grafting: r=−0.33; P=0.03). Physical component score in TAVI increased after 30 days (32.1±6.6 versus 38.9±7.0; P<0.0001) and 6 months (40.4±9.3; P<0.0001); the improvement occurred later in SAVR (baseline: 34.9±10.6; 30 days: 35.9±10.2; 6 months: 42.8±11.2; P<0.001). After TAVI, there were no differences in the short form-12 health outcome scores according to the presence or size of new cerebral infarction. Conclusions-Cerebral microinfarctions are more common after TAVI compared with SAVR but seem to have no negative effect on early (30 days) or medium term (6 months) health-related quality of life. Aortic atheroma (TAVI) and concomitant coronary artery bypass grafting (SAVR) are independent risk factors for cerebral microinfarction. (Circ Cardiovasc Interv. 2015;8:e001913. Key Words: aortic valve stenosis ◼ magnetic resonance imaging ◼ quality of life ◼ transcatheter aortic valve replacement
T ranscatheter aortic valve implantation (TAVI) in patients with symptomatic severe aortic stenosis is an alternative to medical therapy or surgical aortic valve replacement (SAVR) in those at high surgical risk. 1 TAVI has been shown to reduce mortality and improve patient symptoms and healthrelated quality of life (HRQoL). 2, 3 Although TAVI seems cost-effective when compared with SAVR, embolic cerebral infarction remains a concern because of its frequency and the associated morbidity, mortality, and healthcare costs. 4 This will be increasingly important if TAVI is considered for lower risk or younger patient populations.
Previous work has shown that embolic cerebral infarction occurs after both TAVI and SAVR, with the majority remaining subclinical. 3, [5] [6] [7] [8] [9] The incidence of cerebral emboli seems to be greater post TAVI, with no significant difference between the access routes (transfemoral versus transapical) or valve types (Medtronic CoreValve versus Edwards Sapien). 8 The clinical consequences of these silent infarcts and identification of risk factors are yet to be fully established. Two studies have assessed basic cerebral function using a mini-mental state examination pre and post TAVI, demonstrating no significant change at 3 months. 5, 6 We Cerebral Embolism and HRQoL in TAVI and SAVR have described the early (30 days) effect of cerebral emboli on patient HRQoL and identified age and aortic atheroma severity as risk factors. 3 However, there is uncertainty about the long-term significance of these silent infarcts, whether their location determines functional status, and how this compares to a contemporary SAVR group.
The principal aim of this study was to compare the incidence and natural history of cerebral embolization and their impact on medium-term HRQoL between a TAVI and SAVR group. A secondary aim was to determine factors associated with cerebral embolization.
Methods

Study Participants
Patients with severe symptomatic aortic stenosis were prospectively recruited if they were to undergo either SAVR or TAVI at a large tertiary surgical center. Severe aortic stenosis was defined by transthoracic echocardiography with an aortic valve area of <0.8 cm2 and a peak velocity of >4 m/s. Between May 2008 and February 2013, TAVI patients were selected by a multidisciplinary heart team in accordance with contemporary UK guidance. 10 Older, higher risk (based on European System for Cardiac Operative Risk Evaluation [EuroSCORE]) SAVR patients with ≥1 comorbidities were identified for recruitment, so that they more closely represented the TAVI population (complete matching was not possible because of the current UK TAVI guidelines). Exclusion criteria included any contraindication to MRI. The study was approved by the Institutional Ethics Committee and complied with the Declaration of Helsinki. All patients provided written informed consent.
TAVI Procedure
TAVI was performed with the Medtronic CoreValve prosthesis by a single experienced, high-volume operator as previously described. 11 Briefly, all procedures were performed under general anesthesia with x-ray fluoroscopy and transesophageal echocardiographic guidance. All patients received heparin to maintain an activated clotting time >200 s and were treated with dual antiplatelet therapy (aspirin and clopidogrel) for 3 to 6 months post procedure.
SAVR Operation
Midline sternotomy was performed for all surgical patients using intraoperative transesophageal echocardiographic guidance. After standard heparinization, the aorta was cross-clamped and cardiopulmonary bypass was initiated with mild hypothermia. The type and size of surgical prosthesis varied dependent on annulus size, patient characteristics, surgical, and patient preference. Coronary artery bypass grafting was concomitantly performed when indicated.
Cerebral MRI
Cerebral MRI was conducted pre and post procedure (within 7 days) and again at 6 months using identical imaging protocols. MRI was performed on the same 1.5T system for all serial scans for any individual patient (Intera, Philips Healthcare, The Netherlands or Avanto, Siemens Medical Systems, Erlangen, Germany). The imaging protocol consisted of T2-weighted fast field echo, T2 turbo field echo, and diffusion-weighted imaging (DWI; 22 slices, 5-mm thick, 1-mm gap, field of view 350, relative field of view 100). Each scan was independently assessed by 3 experienced Neuroradiologists (A.G., I.D., and M.I.), blinded to clinical details. In the case of disagreement, a consensus view was recorded. Cerebral embolism or microinfarction was defined as a new restricted diffusion lesion on DWI. New cerebral microinfarcts were localized to hemisphere and vascular territory. As previously described, infarct diameter was used to categorize patients into small or large lesion subgroups (<5 or >5 mm; in the case of multiple lesions, the largest lesion was used to determine status). The total volume of microinfarcts (milliliter) were measured off-line using standard postprocessing software (QMass7.2, Medis, Leiden, The Netherlands).
Neurological Assessment and Status
A detailed neurological examination was conducted before intervention and daily after the procedure by an experienced consultant physician until hospital discharge (typically day 7). A National Institutes of Health Stroke Scale score was recorded. Transient ischemic attack was defined as any focal neurological deficit that lasted <24 hours. Stroke was defined as any persistent focal neurological deficit lasting >24 hours.
HRQoL Assessment
Health status was evaluated at baseline, 30 days, and 6 months (Valve Academic Research Consortium recommended time-points) using 2 generic HRQoL questionnaires: short form-12 health outcomes (SF12v2, QualityMetric, Lincoln, RI) and EQ5D (EuroQoL 5 dimensions). The SF12v2 survey covers 8 domains: physical functioning, role limitations because of physical health problems, bodily pain, general health, vitality, social functioning, role limitations because of emotional difficulties, and mental health. Domains are combined to produce an average score related to physical (physical component score [PCS]) and mental (mental component score [MCS]) health. Data are adjusted to give normalized-based scores using dedicated scoring software (QualityMetric Inc, Lincoln, RI).
The EQ5D questionnaire covers 5 domains: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. This provides a utility measure between 0 (death) and 1 (full health). The questionnaire was scored using the UK population time-trade off valuation data set. A visual analogue score (VAS) was also completed by patients indicating their health as a percentage between 0 (worst imaginable health) and 100 (best possible health).
Risk Factors for Embolism
Demographic and procedural risk factors for cerebral embolization were recorded for all patients. The ascending, arch, and descending thoracic aorta were imaged using transesophageal echocardiographic to grade severity of atheroma in accordance with a recognized 5-point scale 12 : 1=normal, 2=severe intimal thickening without protruding atheroma, 3=atheroma <5 mm, 4=atheroma >5 mm, and 5=mobile atheroma of any size. In addition, aortic valve calcification was
WHAT IS KNOWN
• Incidence of cerebral microinfarcts is higher after transcatheter aortic valve implantation compared with surgical aortic valve replacement.
• Health-related quality of life improves after transcatheter aortic valve implantation.
WHAT THE STUDY ADDS
• After propensity correction, transcatheter aortic valve implantation remains a risk factor for cerebral microinfarcts when compared with surgical aortic valve replacement.
• Aortic atheroma (transcatheter aortic valve implantation) and concomitant coronary artery bypass grafting (surgical aortic valve replacement) are independent risk factors for cerebral microinfarcts.
• Cerebral microinfarcts have no medium-term (6 months ) effect on health-related quality of life but contribute to reduced physical health early (30 days) post surgical aortic valve replacement. graded using published criteria: 1=no calcification, 2=mild calcification, 3=moderate calcification, and 4=severe calcification. 13 
Statistical Analysis
Continuous variables are presented as mean±SD, and categorical variables as frequency and percentage. Normality was determined by a Shapiro-Wilk test. Comparative statistics were performed using the Student t test or χ 2 test. Non-normal data were compared with the Mann-Whitney test or Wilcoxon signed-rank test. HRQoL scores (baseline, 30 days, and 6 months) were analyzed using linear mixed-effects modeling with an unstructured covariance matrix and time as the fixed effect and Bonferroni post hoc correction for multiple comparisons. The linear mixed-effects model was used instead of repeated measures ANOVA to overcome any potential impact of missing data and the need for a balanced design.
Our sample size was based on published data to detect a 5-to 10-point difference in SF12v2 summary scores and a 0.1-point difference in EQ5D score. To achieve a power of 80%, we needed 33 patients in each group, with an α error set at 0.05 (2-sided). 14 All analyses were performed using the PASW software (SPSS 19, IBM, Chicago, IL). Two-sided P<0.05 was considered statistically significant. Univariate linear regression analysis was performed using all identified covariates and compared with the number of new infarcts postprocedure. Variables with P≤0.1 were entered into a stepwise multivariable regression analysis. Propensity scores (predictive probability) for receiving TAVI were calculated using a binary logistic regression model (TAVI, yes=1; no=0) with confounding variables entered as covariates (age, sex, EuroSCORE, Society of Thoracic Surgery, body surface area, New York Heart Association Class, diabetes mellitus, hypertension, hypercholestrolemia, atrial fibrillation (AF), stroke, before coronary artery bypass grafting [CABG], peripheral vascular disease, porcelain aorta, valve calcification, and aortic atheroma grade). Propensity score adjustment for number of new cerebral infarcts was performed by linear regression analysis with number of new cerebral infarcts as the dependent variable, and the independent variables were TAVI (yes or no) and the propensity scores.
Results
Patient and Procedural Factors
One hundred eleven consecutive patients were recruited (71 TAVI and 40 SAVR). Baseline patient characteristics are presented in Table 1 . The TAVI group was older (80±6.3 versus 70.8±8.3 years; P<0.001), had higher logistic EuroSCORE, EuroSCORE II, and Society of Thoracic Surgery scores, with a higher prevalence of AF, CABG, peripheral vascular disease, and aortic atheroma ( Table 1) . Procedural data for both TAVI and SAVR are detailed in Table 2 . No major peri-procedural complications were reported in the study population.
Detection of Cerebral Emboli
All 111 (TAVI=71, SAVR=40) patients completed the baseline MRI scan. The majority of patients (108; 97%) completed pre and early postprocedural scans (2 pacemaker implantations: TAVI=1 and SAVR=1; and 1 death: SAVR). Six-month follow-up scans were performed in 66 (59%) patients (TAVI=32, SAVR=34); 38 TAVI patients could not reattend (physically unable to attend the department because of frailty=19, declined a further MRI scan=3, pacemaker inserted in the follow-up period=7; Figure 1 ). Four SAVR patients did not have the 6-month scan (death=1, unable to attend because of poor health=3).
Baseline
The cerebral scan showed that TAVI patients had greater preexisting cerebral microinfarction than the SAVR group (n=26
[37%] versus n=6 [15%]; P=0.012). There was no difference in the baseline distribution of infarction between TAVI and SAVR (anterior, 86 versus 44%; posterior, 14 versus 56%; χ 2 =2.86; P=0.09). Figure 2 shows a typical example of new microinfarction detected by DWI. Figure 3 shows the absolute number of cerebral microinfarcts across the 3 time points for TAVI and SAVR populations.
Post Procedure
Neurological Assessment
Two (2.8%) TAVI patients had early (<30 days) focal and persistent neurological signs such that a diagnosis of minor stroke was made (National Institutes of Health Stroke Scale scores 2 and 4). There was 1 (2.5%) early stroke in the SAVR group (National Institutes of Health Stroke Scale =2). No stroke or 
Health-Related Quality of Life
HRQoL questionnaires were completed at baseline (n=111 [100%]; TAVI, n=71; SAVR, n=40), 30 days (n=97 [87%]; TAVI, n=59; SAVR, n=38), and 6 months (n=96 [86%]; TAVI, n=59; SAVR, n=37).
TAVI HRQoL
In the TAVI group, SF12v2 showed a significant improvement in the physical component score (PCS) >3 time points (P<0.0001). PCS improved from baseline to 30 days (32.1±6.6 versus 38.9±7.0; P<0.0001) and 6 months (32.1±6.6 versus 40.4±9.3; P<0.0001). The mental component score (MCS) did not change from baseline after 30 days (45.2±11.2 versus 46.4±11.2; P=0.66), but significantly improved after 6 months (baseline versus 49.3±9.6; P=0.02). The component scores of physical functioning, bodily pain, general health, and mental health significantly increased 30 days after TAVI (Figure 4 ). There was no change at 30 days for role physical, vitality, social functioning, and role emotional (Figure 4 ). After 6 months, there was a significant improvement in all scores except for mental health (Figure 4) .
The EQ5D score and VAS showed a significant improvement during the study period (Table 3 ). There was no significant change in EQ5D at 30 days, but there was significant improvement at 6 months. The VAS significantly improved from baseline to 30 days and to 6 months, without further significant change between the 30-day and 6-month time periods (Table 3) .
SAVR HRQoL
In the SAVR group, the PCS score of SF12v2 showed an improvement only after 6 months (baseline, 34.4±10.6 versus 30 days, 35.9±10.2; P=0.67 and baseline versus 6 months, 42.8±11.2; P=0.0001). There was a significant decrease in the MCS score at 30 days (baseline, 49.7±12.0 versus 30 days, 44.6±11.5; P=0.01) after SAVR which returned to baseline levels at 6 months (baseline versus 6 months, 51.1±9.4; P=0.54). At 30 days post SAVR, there was no improvement in any of the component scores, whereas there was a significant reduction in social functioning (baseline, 44.4±12.9 versus 30 days, 35.4±11.3; P=0.001). Nevertheless, at 6 months, there were significant improvements in all component scores compared with baseline values (Figure 4) .
The EQ5D and VAS showed a significant difference >3 time points (Table 3 ). There was no significant difference for the EQ5D score between baseline and either 30 days or 6 months; there was, however, a significant improvement between 30 days and 6 months. From baseline, the VAS did not change at 30 days but had significantly improved at 6 months ( Table 3 ). Figure 5 shows the differences in SF12v2 scores from baseline to 30 days, and baseline to 6 months for TAVI and SAVR. At 30 days, mean TAVI scores have improved across all components, whereas SAVR score has generally declined; physical functioning and general health did improve but the change was significantly less than in TAVI ( Figure 5A ). At 6 months, there was a positive improvement in all component scores, and there was no statistically significant difference between TAVI and SAVR ( Figure 5B ). The improvement in PCS score at 30 days was significantly greater for TAVI than SAVR, whereas there was a significant reduction of MCS score in SAVR when compared with that in TAVI patients ( Figure 5C ). At 6 months, there was no statistical difference between TAVI and SAVR ( Figure 4D) . The EQ5D and VAS scores increased >3 time points, but there were no statistically significant differences between TAVI and SAVR.
Comparison of TAVI and SAVR HRQoL Scores
Influence of Cerebral Emboli on HRQoL Scores
The patients who had cerebral MRI and HRQoL assessment were placed into 3 categories: no new infarct, infarcts <5 mm, and infarcts >5 mm (Tables I and II in the Data Supplement). In the TAVI group, there were no differences in the Table I in  the Data Supplement) . However in the SAVR group, PCS and the component scores for physical function and bodily pain were significantly lower at 30 days in those with smaller (<5 mm) infarctions, although these scores had returned to baseline after 6 months (Table II in the Data Supplement) . Overall, there was no difference in EQ5D scores according to the presence or size of new cerebral microinfarction ( Table III in the Data Supplement). The VAS was significantly decreased in the TAVI group with >5 mm infarcts at 30 days (but returned to baseline value at 6 months).
TAVI Patients Without 6-Month Cerebral Imaging
Of the 70 TAVI patients who had a postprocedural head scan, only 32 had the 6-month follow-up scan. Excluding the 5 deaths, this left 33 patients who did not have a follow-up scan. To look for any potential bias because of this, the early DWI findings and HRQoL scores were compared with those that were scanned (follow-up scan versus no follow-up scan). There was no difference in the number of infarcts or volumes (new infarcts, 3.77±3.4 versus 5.07±6.6; P=0.37 and infarct volumes, 0.76±0.8 versus 1.75±3.3 mL; P=0.31). There were no differences in HRQoL summary scores at baseline (PCS, 34.1±6.2 versus 31.0±6.5; P=0.11 and MCS, 45.0±10.9 versus 45.9±11.4; P=0.8) or 30 days (PCS, 41.4±5.5 versus 36.5±8.5; P=0.08 and MCS, 45.9±13.2 versus 47.5±9.0; P=0.66).
Associated Factors for New Cerebral Microinfarction
Univariate analysis for factors associated with new cerebral microinfarction is summarized in Table IV in the Data Supplement. In the TAVI group, atheroma in the arch and descending thoracic aorta and fluoroscopic time were the significant univariate factors associated with new cerebral infarction (Table IV in the Data Supplement). In the multivariable analysis (including the univariate predictors, P≤0.1), the only significant independent predictor was aortic arch atheroma grade (β=2.33; t=3.06; P=0.004 and r=0.46; P=0.0001). In the SAVR group, there were no baseline or procedural variables from univariate analysis that significantly predicted new cerebral infarction (Table IV in the Data Supplement). Multivariable analysis of univariate factors (P≤0.1) showed that concomitant CABG at the time of SAVR was the only statistically significant predictor of cerebral infarction (β=−1.67; t=2.16; P=0.04 and r=−0.33; P=0.03).
Propensity score adjustment for number of new cerebral infarcts showed that despite adjusting for potential confounders, TAVI was still significantly associated with new cerebral infarction (unstandardized coefficient β±SE=2.26±0.85; standardized β=0.25; P=0.009).
Discussion
This relatively large prospective study provides evidence that when compared with SAVR, TAVI results in a higher burden of postprocedural cerebral microinfarcts. Aortic atheroma and concomitant CABG were independent predictors of cerebral infarction for TAVI and SAVR, respectively. New microinfarcts had no effect on the TAVI patients' short-or medium-term mental and physical quality of life. After SAVR, patients with microinfarcts had an initial decline in physical health which recovered by 6 months.
Previous studies, including our own, have shown high rates (77%-84%) of cerebral microinfarction post TAVI. 3, 5 The mechanism of infarction is thought to be embolic in nature. Transcranial Doppler studies have shown an increase in highintensity transient signals during valve alignment and deployment, suggesting that the main source of embolic material may be atheroma, calcification, or even air embolus. 6 We have previously shown a relationship between aortic atheroma and the number of periprocedural infarcts, postulating a mechanism of embolization as bulky catheters are manipulated around the aortic arch. 3 Two studies have subsequently shown that the transfemoral and transapical approaches have similar rates of embolization. 6, 8 This finding does not contradict the risk associated with aortic atheroma as with both access techniques cardiac catheters and wires are passed around the aortic arch.
Identifying risk factors for cerebral emboli is important as this may influence patient selection and the use of cerebral protection devices. 15 We assessed a variety of risk factors, including baseline demographics, comorbidity, and procedural factors. Aortic atheroma, valvuloplasty balloon size, and fluoroscopy time were key factors that influenced the likelihood of TAVI cerebral embolization. Aortic atheroma was an independent predictor of cerebral emboli. This further validates our previous findings and to date remains the only patient-specific risk factor identified for cerebral emboli. 16 The use of larger valvuloplasty balloons could result in greater trauma to the aortic atheroma and hence create a substrate for embolism. Similarly, fluoroscopic time can be considered a surrogate marker for procedural complexity and device manipulation against the aortic wall. Nombela-Franco et al 17 reported balloon post dilatation to predict higher acute cerebrovascular events, whereas later events were best predicted from conventional risks, such as new onset AF, peripheral vascular disease, and cerebrovascular disease.
SAVR is believed to result in cerebral embolization secondary to cannulation of the aorta and stimulation of a systemic inflammatory response induced by cardiopulmonary bypass. 18 Our results show that duration of cross-clamping time and concomitant CABG are associated with a higher rate of cerebral microinfarction consistent with this theory. Differences in procedural event rates could represent the greater age and risk factor profile of TAVI when compared with SAVR patients, as there has not been a study of matched patients to date. However, after propensity correction, our data suggest that the TAVI procedure is still an independent risk factor for cerebral emboli.
The clinical impact of cerebral embolism is of significant concern to patients and physicians. TAVI has a greater risk of early stroke and transient ischemic attack compared with surgery, 19 but by 2 years there seems to be no difference. 20 However, silent cerebral infarcts have been shown to adversely affect patient memory, cognition, and be associated with dementia. 21, 22 Quality of life is an important clinical outcome measure and is 1 of the main reasons that TAVI is conducted. 23 As such, anything negatively affecting HRQoL, such as silent cerebral emboli, would be of concern. This study has shown that for both TAVI and SAVR new cerebral emboli did not detrimentally affect patient-reported HRQoL at 6 months. Interesting differences occur between the 2 procedures from baseline to 30 days, with a decline in physical health in the surgical group. This seemed to be in part related to individuals who had developed cerebral emboli but is also likely to reflect the impact that major surgery (sternotomy, bypass, and Intensive Care Unit) has on the early physical condition of the patient thus affecting social functioning. HRQoL is an important clinical outcome measure but is not a test of higher cognitive function; further research is required to identify any subtle effects that silent cerebral microembolization may have on neuropsychological function after TAVI or SAVR. Indeed, silent cerebral infarction has been associated with global memory loss 21 and postoperative neurocognitive dysfunction after CABG 24 and cardiac procedures, such as AF ablation. 25 For the TAVI procedure, any impact on neurocognitive function will be important to determine whether it is considered in lower risk and younger patients.
Limitations
Because of current TAVI implantation criteria, the groups could not be fully matched for age, comorbidity, or risk factor scores; our findings may be negatively biased against the higher risk TAVI group. Although the sample size may appear small, we had adequate power to detect measurable differences in HRQoL scores. There were many TAVI patients who could not have follow-up scans because of frailty or pacemaker insertion, which may further introduce bias. We did not assess frailty pre and post procedure because the study protocol was already considered arduous for this patient group. The cerebral MRI scans were performed at 1.5T which reliably detects DWI infarcts, but higher field strengths (3.0T) may have greater sensitivity. 25 However, at the time of our study, the CoreValve prosthesis was not approved for 3.0T field strength and on-going clinical trials of cerebral embolic protection devices are at the 1.5T field strength. The study does not explain the full significance of cerebral embolization on patient outcome, in particular the impact on neurocognitive function, and our intention is to follow-up this work with dedicated neuropsychological testing. Finally, our study used CoreValve in isolation, and the findings and outcomes may be different with other valve prostheses.
Conclusions
Postprocedural cerebral microembolic events occur more frequently after TAVI when compared with those after SAVR. Aortic atheroma is the main predictor of cerebral emboli post TAVI, but not post SAVR, where concomitant CABG remains the dominant risk factor. New cerebral microembolization is associated with reduced physical health 30 days post SAVR, but had no detrimental effect on health after either procedure (TAVI or SAVR) in the medium term (6 months).
